Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance

ABSTRACT In a subset of SARS-CoV-2-infected individuals treated with the antiviral nirmatrelvir-ritonavir, the virus rebounds following treatment. The mechanisms driving this rebound are not well understood. We used a mathematical model to describe the longitudinal viral load dynamics of 51 individu...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, Julie Boucau, Rockib Uddin, Caitlin Marino, May Y. Liew, Mamadou Barry, Manish C. Choudhary, Dessie Tien, Karry Su, Zahra Reynolds, Yijia Li, Shruti Sagar, Tammy D. Vyas, Yumeko Kawano, Jeffrey A. Sparks, Sarah P. Hammond, Zachary Wallace, Jatin M. Vyas, Jonathan Z. Li, Mark J. Siedner, Amy K. Barczak, Jacob E. Lemieux, Alan S. Perelson
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology 2025-03-01
coleção:	Journal of Virology
Assuntos:	SARS-CoV-2 viral rebound nirmatrelvir-ritonavir antiviral therapy target cell preservation mathematical model
Acesso em linha:	https://journals.asm.org/doi/10.1128/jvi.01623-24
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!